Figure 2From: Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patientsKaplan–Meier survival analysis for breast cancer patients with (solid line) PTPRO tumor methylation or without (dotted line). (a) overall group; (b) ER+; (c) PR+; (d) HER2-amplified subgroup.Back to article page